Fundraisings and IPOs

Date: 2014-04-11

Type of information: IPO

Company: TxCell (France)

Investors: Auriga Partners (France) Seventure Partners (France) Bpifrance (France)

Amount: €16.2 million

Funding type: IPO

Planned used:

TxCell is a French biopharmaceutical company based in Sophia Antipolis in southern France. It is developing a new generation of personalised cell-based immunotherapies that use the patient’s own cells to treat severe chronic inflammatory and auto-immune diseases. The funds will be used to support clinical development of Ovasave®. Its first candidate drug Ovasave®, now in clinical development, targets patients suffering from Crohn’s disease who are refractory to existing treatments—an estimated 80,000 to 100,000 people a year representing a potential market estimated at around €3 billion. The company’s second candidate drug is Col-Treg, now under development for the treatment of auto-immune uveitis.

Last March, TxCell and Ferring International Center SA have signed a collaboration, option, development and license agreement potentially worth up to € 76 million plus royalties subject to the achievement of milestones. In the agreement, TxCell has granted Ferring an option to acquire an exclusive worldwide license for the development, manufacture and marketing of TxCell’s lead candidate Ovasave® for the treatment of IBD, including Crohn's disease and ulcerative colitis.


* On April 11, 2014,TxCell, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, has announced it has raised €16.2 million through its listing on Euronext Paris (compartment C). TxCell was listed through the admission to trading of 7,860,467 existing shares making up the company’s equity and 2.903.226 new shares issued under a Global Offering. The admission and issue price of TxCell shares was set at €5.58 per share. The company’s market capitalisation stands at around €63.6 million.

* On March 14, 2014, TxCell has announced the filing of its document de base with the French Autorité des marchés financiers under number I.14-008 on March 13, 2014. The registration of the document de base is the first step towards TxCell’s initial public offering of its shares on the regulated market of Euronext Paris. The process is subject to market conditions and to the AMF’s visa on the prospectus for the transaction.

Therapeutic area: Autoimmune diseases – Inflammatory diseases

Is general: Yes